about
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancerMolecular landscape of prostate cancer: implications for current clinical trialsFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsMolecular landscape of pancreatic cancer: implications for current clinical trialsSafety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare CancersPhiladelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeuticsSuccessful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alphaJuice plus or toxicity plusResponse of histiocytoses to imatinib mesylate: fire to ashesBRAF mutations in advanced cancers: clinical characteristics and outcomesConsensus recommendations to accelerate clinical trials for neurofibromatosis type 2.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase.Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.Phase II study of alemtuzumab in chronic lymphoproliferative disorders.Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited.Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome.A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersPhase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumorsA phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trialPhase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer.
P50
Q24634545-F82393AE-CA33-487F-8B73-E1C282592C1FQ26799585-E466C5A8-A0C5-4722-AF81-6BEB5CD84A38Q26801718-3975F019-BC3B-4B72-9D86-1B546E9D3D53Q26824528-FC3F464C-7C4B-4179-98F2-2AF6D699DE98Q27851852-EE3E7990-2A1E-45C1-87D5-9F50D61FBBBCQ27851856-2A6CF81F-47A7-4BD2-B26D-5CF188828DDAQ28087174-0468B883-E763-42FF-A6AE-167258B70FADQ28205012-CD51AB3F-A962-494C-8EC5-C1E5ECB34F25Q28261747-054B62DF-86C7-4BFA-8FDF-66F7508D9BCCQ28271471-D4DEBB91-0681-4EC5-A9C8-DA695A9DC123Q28291341-740DAB0C-53B7-47C3-A6B8-A8FFD948ECB1Q28743591-C0DAD3DF-F34F-476F-BC76-41321349C668Q30406342-3436ED03-8E7C-4084-841E-123C2B0A9ACEQ30440530-22B0EE8D-74DD-49E3-B63B-DDE975909267Q30458310-4A4ED349-CF92-42BB-83EF-B5FDA04380DFQ30487546-7DABAA05-C97D-4BA4-8344-01D32F219825Q33163062-23F54F83-8654-450E-A586-7E2FBE9E979DQ33349421-113D2186-CEE9-41C1-BBFA-15B389A6C9EFQ33357763-B2FDFA7B-D35D-4D21-AA3F-F166279B2334Q33358735-EB33F57B-9A8A-45EB-A957-42411500A5BBQ33365238-F5844CAD-61F5-436B-87A2-BD6BEABA3113Q33373122-89818445-3234-4250-9EF4-7B12E152FE1EQ33374053-49484860-ECE3-4B3C-B115-DD2B38374385Q33381378-F45EC3C6-1247-4565-899E-58BF0640AD6DQ33388487-FF68D7B6-634E-4F64-B07B-DAE1E8594139Q33390290-E22F299D-7124-48FE-A74C-AC4A3F278C57Q33392260-CAC84B21-F084-4BE1-94CE-4748E0134E05Q33393523-AB942556-3132-4D92-BD12-21E8B1C9E23AQ33394175-F086106A-569E-4C56-B36D-37E2FDEAE542Q33396217-289D9AE7-E70D-42AD-B24A-3034D6BC8564Q33396217-AC75B6DD-84B8-4368-BFEA-6C068F83B11EQ33396217-D85C10DF-8181-442D-A3B9-ED66622AE756Q33397006-827F39B5-404B-45D5-BC56-3CC8FEBD0FBCQ33400495-ED7630A6-C569-4B70-A76C-C2FBB9BD4957Q33400889-B912FC56-3434-4956-AD63-06EC05A779D2Q33404541-229430B9-BF6D-4BF1-B722-DA65407BFE2EQ33405571-C3391339-91EC-402B-BD75-115D406B6EF3Q33407219-DFD9AE7C-7982-49CF-BBD9-F9D7E5226953Q33407570-E3D88980-0592-4927-A03D-665181901E56Q33408279-969D4687-856E-405B-8E3E-49CAF6D83A9A
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Razelle Kurzrock
@ast
Razelle Kurzrock
@en
Razelle Kurzrock
@es
Razelle Kurzrock
@nl
type
label
Razelle Kurzrock
@ast
Razelle Kurzrock
@en
Razelle Kurzrock
@es
Razelle Kurzrock
@nl
prefLabel
Razelle Kurzrock
@ast
Razelle Kurzrock
@en
Razelle Kurzrock
@es
Razelle Kurzrock
@nl
P1006
P214
P244
P1006
P106
P2002
Dr_R_Kurzrock
P21
P214
P244
P31
P496
0000-0003-4110-1214
P7859
lccn-n92800469